Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.

Author: BasquieraAna, BernardHaydee I, IastrebnerMarcelo, JangJun Ho, JungChul Won, KimDong Hwan, KimKihyun, KleinGraciela, KorinJorge, NuciforaElsa, OrlandoSergio, SackmannFederico, SantiniFernando, TabordaGustavo

Paper Details 
Original Abstract of the Article :
This multicenter, open-label study evaluated the efficacy and safety of decitabine in patients from Argentina and South Korea with myelodysplastic syndromes or chronic myelomonocytic leukemia. Of 106 patients who received decitabine 20 mg/m(2) intravenously over 1 h once daily for 5 days in 4-week c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.3109/10428194.2010.524324

データ提供:米国国立医学図書館(NLM)

Decitabine in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Argentinian/South Korean Multi-Institutional Clinical Experience

Imagine a vast desert, where the sands represent the complex world of hematologic malignancies, like myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This study, published in [Journal Name], explores the effectiveness of a drug called decitabine in treating these challenging conditions.

Decitabine Shows Promise in Treating MDS and CMML

This multi-center study, conducted across Argentina and South Korea, investigated the efficacy and safety of decitabine in patients with MDS and CMML. The researchers found that decitabine, like a nourishing spring in the desert, led to a significant improvement rate of 35% in patients. This improvement included complete responses, partial responses, and hematologic improvement. Furthermore, the overall survival at two years was 71%, indicating a positive impact on the long-term outlook for patients with these conditions.

Navigating the Side Effects of Decitabine Treatment

While decitabine showed promising results, it's important to acknowledge the potential side effects, such as febrile neutropenia, thrombocytopenia, bleeding, asthenia, fatigue, and eosinophilia. These side effects, like desert mirages, can appear and disappear, requiring careful monitoring and management. However, the study highlights the importance of decitabine as a viable treatment option for MDS and CMML, particularly in clinical practice settings in South America and Asia.

Dr. Camel's Conclusion

This research provides a valuable roadmap for navigating the complexities of treating MDS and CMML, offering a beacon of hope for patients seeking effective treatment options. The study emphasizes the importance of carefully weighing the potential benefits and risks of decitabine therapy, ensuring that patients receive personalized care that addresses their unique needs and maximizes their chances of achieving a positive outcome.
Date :
  1. Date Completed 2011-03-31
  2. Date Revised 2019-01-16
Further Info :

Pubmed ID

20929328

DOI: Digital Object Identifier

10.3109/10428194.2010.524324

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.